Significant advances in the genetic and molecular characterization of cancer have led to the development of effective immunotherapies. These therapeutics help the host immune system recognize cancer as foreign, promote the immune system, and relieve the inhibition that allows growth and spread of tumors. Experience with various immunotherapies, particularly the immunomodulatory monoclonal antibody ipilimumab, has demonstrated that unique patterns of response may be encountered that cannot be adequately captured by traditional response criteria, such as the World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), which have been used primarily with cytotoxic chemotherapies. In response to these observations, several novel response criteria have been developed to evaluate patients who receive immunotherapy, including immune-related response criteria (irRC), immune-related RECIST (irRECIST), and immune RECIST (iRECIST). These criteria are typically used in conjunction with RECIST version 1.1 in the clinical trial setting, because approval of new therapeutics by the US Food and Drug Administration relies on the responses derived from RECIST version 1.1. Finally, a wide variety of immune-related adverse events may affect patients who receive immunotherapy, many of which can be identified on imaging studies such as computed tomography, magnetic resonance imaging, and 2-deoxy-2-(fluorine-18)fluoro-D-glucose-positron emission tomography/computed tomography. In this review, the authors present the role of imaging in the evaluation of patients treated with immunotherapy, including the background and application of irRC, irRECIST, and iRECIST; the imaging of immune-related adverse events; and future directions in advanced imaging of immunotherapy. Cancer 2018;124:2906-22. V C 2018 American Cancer Society.
INTRODUCTION
Significant advances in the genetic and molecular characterization of cancer have led to the development of effective immunotherapies, which assist the host immune system in recognizing cancer as foreign, stimulate the immune system, and relieve the inhibition that allows growth and spread of tumors. In contrast to traditional chemotherapy, which mainly targets rapidly dividing cells, and targeted therapies, which interfere with important molecular events in cancer cells that drive growth and invasion, immunotherapy attempts to assist in the recognition of cancer as foreign by the host immune system, stimulate the immune system, and relieve the inhibition that allows tumor growth and spread. Immunotherapy is described as either active or passive, depending on its interaction with the host immune system and the type of response elicited. For instance, the active immune response involves humoral and/or cell-mediated immunity, whereas the passive immune response requires no activation of the immune system and involves passively infused, preformed antitumor immunoglobulins to tumor-associated antigens.
As the treatment options for cancer continue to advance, the development of imaging criteria for appropriately assessing response to therapy is critical. Increased use of immunotherapy has demonstrated a wide variety of imaging features and patterns of disease that are imperative to understand when assessing patients. [1] [2] [3] Extensive experience with ipilimumab, an immunomodulatory monoclonal antibody, has demonstrated that several unique responses may be observed during the course of treatment with immunotherapies that are not adequately captured by traditional response criteria like the World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST). 4 For instance, in contrast to conventional response criteria, a transient increase followed by a subsequent decrease may be encountered as treatment response (so called pseudoprogression). However, delayed or subsequent regression has been demonstrated in only about 10% of patients with melanoma. 4 Because of these observations, several response criteria have been developed to evaluate patients who receive immunotherapy, including immune-related response criteria (irRC), immune-related RECIST (irRECIST), and immune RECIST (iRECIST). 4, 5 With the increasing use of immunotherapy, it is becoming easier to recognize numerous immune-related adverse events, such as colitis, hepatitis, pneumonitis, and various endocrine toxicities. 2, 6 It is important for radiologists and other providers to be familiar with the imaging manifestations of immune-related adverse events in patients who are receiving immunotherapy and to distinguish these findings from progression of disease.
In this review, we present the role of imaging in the evaluation of patients treated with immunotherapy, including specific response criteria, such as irRC, irRE-CIST, and iRECIST, and the imaging of immune-related adverse events.
EVALUATION OF TREATMENT RESPONSE
Investigators traditionally have relied on response criteria to evaluate the effectiveness of chemotherapy, the most widely used of which have been the WHO criteria and RECIST guidelines. The WHO criteria were the first standardized response criteria but were limited by several factors. 7 The original RECIST guidelines (RECIST 1.0), published in 2000, were developed by a large, international group of investigators to standardize the characterization of treatment efficacy using specific response definitions. 8 This was followed by the release of revised RECIST criteria (RECIST 1.1) in in 2009. 9 These criteria are optimized to evaluate the cytotoxic effects of chemotherapeutic agents on solid tumors, and specific effects can be identified on imaging studies usually within a few weeks of therapy. These guidelines depend on a decrease in the size of tumors and the absence of new lesions. 1, 4 Therefore, it is assumed that a significant increase in tumor growth and/or the appearance of new lesions indicates progressive disease (PD). Typically, chemotherapy is discontinued once progressive disease (PD) is documented. A significant limitation of these traditional response criteria is that several specific patterns of response known to occur in patients who receive treatment with other agents, such as antiangiogenic therapies or immune therapies, are not appropriately captured. For instance, new agents, such as cytokines, cancer vaccines, and immunomodulatory monoclonal antibodies, may produce a delayed response, a transient increase in size followed by tumor shrinkage, and/or the appearance of new lesions, which become stable, decrease, or resolve without further treatment. 4 However, only about 10% of patients who receive immunotherapy demonstrate regression after initial progression. 4 To reflect these observations and overcome existing limitations, many modifications have been made to traditional response criteria; however, in many instances, these criteria have not been standardized and incorporated into clinical trials in an organized fashion. Thus, new criteria, such as irRC, irRECIST, and iRECIST, have been developed to assist investigators and clinicians in distinguishing between patients who are and are not responding to a particular treatment as early as possible.
Immune-Related Response Criteria

Background and development
In 2004 and 2005, a multidisciplinary group of experts presented and analyzed their experiences with immunotherapy and treatment response. This group outlined several key points: 1) Measurable antitumor activity may take longer to manifest for immunotherapies than for traditional chemotherapy; 2) responses to immunotherapy may occur after the identification of PD by traditional response criteria, such as RECIST 1.1; 3) continuation of immunotherapy may be appropriate in clinically stable patients who have PD; 4) consideration of clinically insignificant PD is recommended (such as the development of new, small lesions in a patient with lesions that are responding to therapy); and 5) prolonged and durable stable disease (SD) may represent effective therapy. 4 An analysis of 487 patients with unresectable stage III or IV melanoma who received treatment with ipilimumab (a human monoclonal antibody that blocks cytotoxic Tlymphocyte antigen-4 [CTLA-4]) in 3 multicenter, phase 2 clinical trials demonstrated 4 patterns of clinical response, including: 1) a decrease in lesion size without new disease, 2) SD after the completion of therapy, 3) a delay in response after an initial increase in total tumor burden (TTB), and 4) the appearance of new lesions before a decrease in tumor size. The first 2 response patterns were appropriately captured with conventional response criteria, including responses in baseline lesions without new lesions and, in some patients, SD followed by a slow, steady decline in disease. The other 2 response patterns were novel and included responses after an initial increase in TTB (so-called pseudoprogression) and a reduction in TTB during or after the appearance of new lesion(s). 4 The immune-related response criteria (irRC) published by Wolchok et al in 2009 were based on these observed patterns.
Principles and application
The irRC were adapted from the WHO criteria and designed to address treatment response and recommendations for imaging follow-up of patients who received immunotherapy. There are many differences between conventional response criteria, such as RECIST 1.1, and irRC (Table 1) . For instance, the irRC do not specifically address which imaging modalities should be used in the evaluation of treatment response, and anatomic and combined anatomic and metabolic methods of assessment are frequently used interchangeably in clinical trials. However, in contrast to RECIST 1.1, only anatomic measurements are considered. For all cases, the TTB, defined as the sum of the products of the 2 greatest perpendicular dimensions (SPD) of all index lesions (measured in mm 2 ), is calculated at baseline and at all subsequent time points. Target lesions must measure 5 3 5 mm, and up to 5 may be selected per organ (up to 10 lesions involving visceral organs and 5 cutaneous lesions). At subsequent time points, the TTB is calculated by the addition of the SPD of all target lesions and the SPD of any new measurable lesions (TTB 5 SPD index lesions 1 SPD new measurable lesions). This differs significantly from conventional response criteria, which consider all new lesions as PD.
Once the TTB is calculated, an overall response category is assigned to each case based on changes between time point assessments. These response categories include a complete response (irCR), a partial response (irPR), SD (irSD), and PD (irPD) ( Table 2 ). The TTB must increase by 25% and must be confirmed by repeat imaging at a minimum of 4 weeks later to constitute definitive irPD. New lesions or a perceived increase in TTB because of pseudoprogression can result from immune cell recruitment to sites of microscopic disease ( Figs. 1 and 2 ). In irRC, all patients who have an irCR, irPR, and irPD must have repeat imaging performed at a minimum of 4 weeks later for confirmation if they are clinically stable; however, follow-up with observation alone may not be appropriate for those who have a rapid decline in performance status. The response of patients who have irSD, particularly those with a slowly declining tumor burden (25% from baseline at the last tumor assessment), is considered clinically meaningful, because they exhibit an objectively measurable reduction in TTB without reaching the 50% threshold that defines irPR. In addition, it is recommended that, after the completion of therapy, an evaluation of treatment response should be made with 2 consecutive follow-up imaging studies at least 4 weeks apart because of the potential for a delayed response.
Limitations
Although the irRC introduced several advancements in terms of assessing response in patients treated with immunotherapy, several limitations have been described. For instance, the irRC provide no guidance regarding the number of lesions that should be included, and assessing a relatively large number of lesions per organ could be relatively time consuming in patients with extensive disease. 2, 10 In addition, there is no specific guidance regarding the assessment of lymph node disease. The reproducibility of bidimensional assessment also is lower than that of unidimensional assessment. Finally, although nontarget unequivocal progression contributes to irCR based on the initial description by Wolchok and colleagues, 4 it does not do so with respect to irPD; however, this was not used in the majority of studies that applied the irRC.
Immune-Related RECIST
Background and development
Nishino and colleagues evaluated the impact of reducing the number of target lesions and using unidimensional measurements to assess patients who received ipilimumab for melanoma. Those authors demonstrated that unidimensional measurements simulating RECIST 1.1 were more reproducible compared with the bidimensional measurements of irRC. 5 The group recommended that the number of targets could be reduced to up to 2 per organ and up to 5 in total, as defined in RECIST 1.1, and proposed the use of unidimensional measurements to assess response to immunotherapy in solid tumors given their relative simplicity, higher reproducibility, and high concordance with the bidimensional measurements of irRC. 5 
Principles and application
The irRECIST are very similar to RECIST 1.1 in terms of guidance regarding the selection of imaging modalities, definitions of measureable and unmeasurable disease, and criteria for selecting target and nontarget lesions. 11 For example, target lesions may include nonlymph node lesions measuring 10 mm in the long axis or lymph nodes measuring 15 mm in the short axis. As in RECIST 1.1, up to 5 total target lesions may be selected with a maximum of 2 per organ, and the measurements of these lesions are recorded as the total measured tumor burden (TMTB). Nontarget lesions may include measurable lesions not selected as target lesions, sites of nonmeasurable disease, and lesions that may be difficult to measure in a reproducible manner, such as bone lesions, leptomeningeal metastases, inflammatory breast disease, malignant ascites, pleural or pericardial effusions, and lymphangitic carcinomatosis. It is generally recommended that previously treated lesions should not be selected as target lesions unless local progression has been documented.
A significant difference between irRECIST and RECIST 1.1 and other response criteria is the method by which new lesions are incorporated into the assessment of treatment response. In irRECIST, new lesions may be characterized as measurable or unmeasurable, and those selected as new target lesions must meet the same criteria for inclusion as the lesions that were present at baseline. When multiple qualifying lesions are present, it is recommended that they be prioritized according to size, with the largest lesions selected as new target lesions. In total, 5 new target lesions may be selected, with a maximum of 2 per organ. New measurable lesions that are not selected as target lesions may be classified as new nonmeasurable lesions and can be qualitatively followed. When new measurable lesions are selected as target lesions, the greatest dimensions of both existing and new nonlymph node target lesions and the short axis dimensions of both existing and new lymph node target lesions constitute the TMTB. This represents a significant difference from RECIST 1.1, in which the appearance of new lesions is always considered PD, and therapy typically is discontinued, without a method for following these new lesions. Similar to irRC, the overall response categories for irRECIST include irCR, irSD, irPR, and irPD and are based on changes in the TMTB of measured target lesions (baseline and new), nontarget lesion assessment, and new nonmeasurable lesions (Table 3) . These response categories have defined thresholds for irPR and irPD that are aligned with RECIST 1.1. For patients with irPD and a minimal TMTB percentage increase >20%, particularly early on in therapy (such as during the first 12 weeks of treatment), confirmatory evaluation may be considered.
Limitations
One of the most significant limitations of irRECIST is that these recommendations have not always been consistently applied, raising concerns among clinicians and researchers regarding the comparability of data and results across various clinical trials. In addition, studies that demonstrated the efficacy of irRECIST were performed on relatively small cohorts of patients, and more detailed evaluation of irRECIST 1.1 is still required. Finally, in contrast to iRECIST, with irRECIST, a delayed response after pseudoprogression that does not reach irSD will result in a confirmation of irPD.
Immune RECIST
Background and development
In an effort to standardize and validate response criteria, the RECIST working group evaluated data collected from prospective clinical trials using immunotherapy and RECIST 1.1. 12 That group reported that most clinical trials involving immunotherapy used RECIST 1.1 to define primary and secondary efficacy-based endpoints and used the irRC or modified definitions of RECIST for exploratory endpoints. 13, 14 There was significant variability in which criteria were incorporated clinically within different groups, raising concerns about the interpretation of pooled data sets. In addition, most clinical trials that applied immune-modified criteria used independent imaging review by a commercial entity for those criteria rather than investigator assessments. In response to the limitations of existing response criteria and these observations, the RECIST working group developed guidelines for the use of modified RECIST termed iRECIST to ensure consistent design and data collection and to facilitate the ongoing collection of data from clinical trials and ultimate validation of the guidelines.
Principles and application
The tenets of iRECIST are very similar to those of RECIST 1.1 and irRECIST regarding the recommended imaging modalities, definitions of measureable and unmeasurable disease, and criteria for selecting target and nontarget lesions. 12 New lesions may be classified as target or nontarget lesions and are evaluated as in RECIST 1.1. However, target and nontarget lesions are recorded separately and are not included in the sum of the greatest dimensions of all target lesions, in contrast to irRECIST.
The overall response categories for iRECIST include iCR, iSD, iPR, unconfirmed progressive disease (iUPD), and confirmed progressive disease (iCPD), which are designed to allow for the identification and improved characterization of atypical responses 12 (Table  4) . For target lesions, iCR, iPR, and iSD all can be assigned after iUPD has been documented, as long as iCPD has not been achieved. For nontarget lesions, iUPD may be documented before iCR or when the criteria for neither iCR nor iPD have been met (referred to as non-iCPD/non-iUPD) and can be assigned several times, as long as iCPD has not been achieved. The appearance of new lesions results in iUPD; however, this requires confirmation by a further increase in size (or in the number of new lesions) in the lesion category in which progression was first identified (target or nontarget) or by progression in lesion categories that did not previously meet RECIST 1.1 progression criteria on an examination performed 4 to 8 weeks after iUPD. For instance, iCPD may be assigned if additional new lesions appear or if there is a further increase in the size of previous new lesions (5 mm for the sum of target lesions or any increase in nontarget lesions) on the subsequent examination. However, in the case of iUPD and no change, if there is a decrease in tumor burden compared with the baseline study that meets the criteria for iCR, iPR, or iSD, then iUPD must be reached again and confirmed at the next time point for iCPD to have been achieved. If there is no change in tumor size or extent, then the time point response remains iUPD.
The RECIST working group recommends that treatment beyond initial RECIST 1.1-defined progression (iUPD) should/could only allow patients who are clinically stable to continue on treatment until the next assessment. This should be performed 4 weeks later but no longer than 8 weeks later, to ensure that patients remain fit for salvage therapies. All decisions regarding continuation or discontinuation of therapy should be made by the oncologist and patient.
IMPLEMENTATION OF RESPONSE CRITERIA IN CLINICAL TRIALS
Although these new response criteria have been developed with principles of immunotherapy in mind, it should be noted that the current recommendation is for them to be used alongside RECIST 1.1 in clinical trials, because these conventional criteria are used by the US Food and Drug Administration for decisions regarding the approval of therapeutics. For instance, the irRC have been used in several clinical trials alongside RECIST 1.1 in which the patient continues therapy beyond initial PD provided there is investigator-assessed clinical benefit and the patient tolerates the therapy. In this instance, the use of the irRC is beneficial to avoid premature termination of an effective immunotherapy with pseudoprogression when evaluating treatment response with the imaging modalities that are currently available. Hodi and colleagues compared irRC and RECIST 1.1 in patients with advanced melanoma who received pembrolizumab and observed that RECIST 1.1 underestimated the therapy benefit, as determined by overall survival, in 15% of patients.
14 Those authors suggested that the use of modified criteria that permit treatment beyond initial PD determined by RECIST 1.1 may prevent premature cessation of treatment. However, atypical response rates for other tumor entities (such as lung cancer and renal cancer) seem to be inferior, and real progression might be more likely.
As a general limitation, all of these response criteria are defined for anticancer response evaluation in clinical trials of solid tumors with a distinct start point (baseline) and endpoint (tumor progression). Many oncologists currently use RECIST 1.1, irRECIST, and iRECIST in their daily clinical practice to follow their patients with cancer by repeated imaging studies and make decisions about continued therapy on the basis of both objective and symptomatic criteria. However, these criteria may be limited and are not always appropriate for routine clinical use in normal clinical therapy schemas, which frequently involve pauses of treatment, modification of drug dosage, combined systemic and local tumor therapy, and treatment beyond progression, which are not addressed by these criteria. scan from a man aged 41 years with melanoma who received immunotherapy reveals that numerous, small pulmonary nodules are present along the bronchovascular bundles and in the subpleural regions, compatible with a perilymphatic pattern (arrows). (B) A contrast-enhanced, axial CT scan from a woman aged 37 years with lung cancer who received immunotherapy demonstrates multiple, ill-defined pulmonary nodules in a perilymphatic distribution (arrows) and thickening of bronchovascular bundles and interlobular septa in the left lung. In both of these patients, the pulmonary findings resolved after discontinuation of therapy, and sarcoid-like reaction was diagnosed. Sarcoid-like reaction is a rare complication that can manifest with multiple micronodules with or without ground-glass opacities and/or mediastinal/hilar lymphadenopathy. from increased FDG uptake by inflammatory processes, which is an issue, because immunotherapy elicits a natural inflammatory response, and immune-related adverse events also may demonstrate increased FDG uptake. Two studies in patients with melanoma demonstrated the inability of FDG-PET/CT to differentiate between patients who had pseudoprogression because of inflammatory infiltrate and those who had actual PD. 15, 16 Cho et al evaluated the ability of FDG-PET/CT in conjunction with other imaging modalities to predict early response to therapy in patients with advanced melanoma who receive treatment with several checkpoint inhibitors. 17 At each post-treatment time point, response was assessed based on RECIST 1.1, irRC, Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST 1.0), and European Organization for Research and Treatment of Cancer criteria. Those authors developed criteria comprised of anatomic and functional information that predicted eventual response with 100% sensitivity, 93% specificity, and 95% accuracy. FDG-PET/CT has demonstrated benefit in evaluating the response of patients with melanoma to treatment with BRAF and MEK inhibitors 18 but has proven to be inadequate in examining responses to immunotherapy for other cancers, such as renal cell carcinoma. 
Immune-Related Adverse Events
Over the course of therapy, unintended autoimmunemediated complications may develop because of alterations in the host immune system. Complications related to immunotherapy are referred to as immune-related adverse events and may be the result of the induction of either autoimmunity or a proinflammatory state. 20 These events tend to resolve with discontinuation of therapy, suggesting that they are not true autoimmune processes but are the result of general immunologic enhancement. 6 Analysis of clinical trial data has demonstrated significant variability in the reporting quality of adverse events, 21, 22 which is typically inadequate. [23] [24] [25] The most common immune-related adverse event is dermatologic toxicity, which may result in skin rash, and is typically low grade; however, toxic necrotizing epidermolysis mucositis has been reported. 2, 6 Additional effects include enterocolitis, hepatitis, pneumonitis, and endocrinopathies, such as hypophysitis, thyroiditis, and adrenal insufficiency. Other complications of immunotherapy include sarcoid-like reaction, acute kidney injury, pancreatitis, neurotoxicity, cardiotoxicity, and ophthalmologic toxicity. Severe colitis has the highest mortality and worst outcome associated with immune-related adverse events. 26 
Imaging of Immune-Related Adverse Events
In evaluating patients who receive immunotherapy, it is imperative for radiologists and other providers to recognize unique adverse events to guide appropriate management and prevent misinterpretation of studies. Side effects often result in abnormalities that may be identified on CT, MR imaging, or FDG-PET/CT performed for restaging and/or surveillance. Immune-related adverse effects may produce findings and metabolic changes before the appearance of clinical symptoms, allowing early change of therapy. 1 Pneumonitis is the most common immune-related adverse event in the chest. Chest radiography may be the first imaging modality to demonstrate abnormalities attributable to pneumonitis because of its widespread availability and use; however, these findings are typically incompletely characterized and nonspecific and are optimally evaluated on chest CT. Naidoo and colleagues demonstrated that only 67% of cases resulted in identifiable findings. 27 In their study, several different patterns of disease were identified, including: 1) a cryptogenic organizing pneumonia (COP)-like pattern (Fig. 3) , 2) ground-glass opacities (Fig. 4), 3 ) an interstitial pattern, 4) a hypersensitivity pneumonitis-like pattern, and 5) pneumonitis not otherwise specified. The imaging findings present in pneumonitis may evolve over time. For instance, cases that are characterized by a COP-like pattern may develop extensive ground-glass opacities. Others with a predominantly ground-glass pattern may develop interstitial abnormalities. A study of patients with nivolumab-induced pneumonitis described 4 patterns on chest CT: COP, nonspecific interstitial pneumonia, hypersensitivity pneumonitis, and acute interstitial pneumonia/acute respiratory distress syndrome. 28 The COP-like pattern manifests with patchy ground-glass opacities and consolidation in a subpleural, peribronchial, or band pattern, which may be observed with the reversed halo sign. The nonspecific interstitial pneumonia pattern includes bilateral ground-glass opacities with reticular opacities, traction bronchiectasis or bronchiolectasis, and minimal or absent honeycombing in a basal distribution with subpleural sparing. 29, 30 The hypersensitivity pneumonitis pattern results in centrilobular nodules and mosaic attenuation of the lung parenchyma because of air trapping with an upper lobe-predominant distribution. 30 Finally, the acute interstitial pneumonia/acute respiratory distress syndrome pattern includes patchy, bilateral ground-glass opacities with consolidation in the dependent lung. 30 Pneumonitis occasionally may result in the appearance of nodular opacities in the lungs; however, none of these findings should be misinterpreted as recurrent disease.
Sarcoid-like reaction is a rare immune-related adverse event that can result in numerous small pulmonary nodules in a perilymphatic distribution (along the bronchovascular bundles and in the subpleural regions) with or without ground-glass opacities and/or mediastinal/hilar lymphadenopathy 31 (Figs. 5 and 6 ). Involvement of the airways is an uncommon complication of immunotherapy that tends to affect the trachea. Cardiovascular abnormalities may be encountered, the most common of which is pericarditis, which can produce a pericardial effusion and/or pericardial thickening on CT. Imaging findings suggestive of ventricular interdependence and constrictive, effusive physiology (including septal bounce and respiratory septal shift) may be present on echocardiography and MR imaging. [32] [33] [34] The most common complication involving the thyroid gland is thyroiditis, which may be identified on iodine-123 thyroid scintigraphy and/or ultrasound. On CT, the thyroid gland is typically enlarged and demonstrates heterogeneously low attenuation (Fig. 7) . Immune-related thyroiditis may be identified on FDG-PET/CT as diffusely increased FDG uptake (Fig. 7) .
Several immune-related adverse events may affect the abdomen and pelvis, the most common of which include colitis and hepatitis. Colitis is a significant clinical complication that has the highest mortality of all immune-related adverse events, and prolonged time to diagnosis and management is associated with poor outcomes. 35 On CT and MR imaging, immune-related colitis may manifest as segmental or diffuse wall thickening, mucosal enhancement, submucosal edema, air-fluid levels, infiltration of the pericolonic fat, and ascites (Fig. 8) . Segmental and diffuse patterns of colitis were observed with ipilimumab treatment: the former manifested clinically with watery or bloody diarrhea, and the latter resulted in watery diarrhea 36 . Other adverse events that may affect the gastrointestinal tract include perforation and bleeding. Immune-related pancreatitis results in imaging findings similar to those from acute pancreatitis unrelated to immunotherapy. On CT, enlargement and an edematous appearance of the pancreas with adjacent fat stranding, edema, and free fluid are most common 37 ( Fig. 9) . Increased FDG uptake may be present on FDG-PET/CT 38 (Fig. 9) . Autoimmune hepatitis may result in periportal or portal vein hyperechogenicity on ultrasound and periportal edema and hypoattenuation of the edematous liver parenchyma on CT. 39 Involvement of the biliary system (cholangiopathy) may manifest as thickening of the bile duct wall and/or biliary ductal dilatation (Fig.  10 ). Other abnormalities, including endocrinopathies like hypophysitis (Fig. 11) and adrenal insufficiency, also may be present. On MR imaging, hypophysitis manifests as mild-to-moderate, diffuse pituitary enlargement without compression of the optic chiasm. Thickening of the pituitary gland is often present. After the administration of intravenous gadolinium contrast material, homogeneous and heterogenous pituitary enhancement may be observed. 40 
FUTURE DIRECTIONS
Although irRC, irRECIST, and iRECIST represent continual improvement over the conventional WHO and RECIST criteria for evaluating response to immunotherapy, limitations and challenges remain, and further refinements are warranted. In this effort, there is ongoing work to develop volumetric imaging, dynamic contrastenhanced imaging, and molecular imaging for optimal evaluation of immunotherapy response and immunerelated adverse events. Several novel PET radiotracers involving amino acids, nucleotides, choline, and S receptor to detect cell proliferation or cell death are currently being investigated. 41 In addition, investigational use of MR imaging for depicting apoptosis and cell lysis to monitor tumor response to immunotherapy also has been reported. 42 Other noninvasive imaging strategies are in various stages of development and implementation. Immuno-PET imaging is a noninvasive, quantitative method of imaging the whole body using radiolabeled monoclonal antibodies that can provide a means to evaluate antibody drug pharmacokinetics and the expression of cell surface markers of disease. 43 Currently, immuno-PET imaging is performed using copper-64 (64Cu)-labeled and zirconium-89 (89Zr)-labeled antibodies. Work has demonstrated that the detection of programmed death 1/programmed death ligand 1 (PD-1/ PD-L1) and/or CTLA4 with immuno-PET, as well as single-photon emission CT (SPECT) radiolabeled with indium-111 (In111), may improve patient identification, stratification, and the early assessment of response. 44 Recently, a preclinical study using granzyme B, a downstream effector of tumoral cytotoxic T cells, distinguished treated responders from nonresponders with excellent predictive ability. 45 In addition, the group evaluated the clinical value of a granzyme B imaging paradigm in which they analyzed biopsy specimens from patients with melanoma who were receiving checkpoint inhibitor therapy.
In that study, there was a marked differential in granzyme B expression between treated responders and nonresponders. The study suggests that granzyme B PET imaging can serve as a quantitatively useful predictive biomarker for efficacious responses to cancer immunotherapy. In another preclinical study, 89Zr-desferrioxamine-labeled anti-CD8 cys-diabody (89Zr-malDFO-169 cDb) immuno-PET was developed for the tracking of endogenous CD8-positive T cells, and the investigators observed that the technique could detect changes in systemic CD8-positive tumor-infiltrating lymphocytes in murine tumor immunotherapy models. 46 In a different study involving 64Cu-radiolabeled atezolizumab, specific binding to tumor cells in vitro based on PET/CT imaging correlated with PD-L1 expression levels. 47 Other PET studies have reported the feasibility of using peptide or small-molecule compounds radiolabeled with gallium-68 or 111In to assess PD-L1 expression. 48, 49 The term radiomics has been used to describe the extraction of advanced quantitative imaging features related to the underlying molecular features and phenotype of tumors from imaging modalities like CT, PET/ CT, and MR imaging. In contrast to the standard qualitative imaging characteristics of neoplasms that are routinely evaluated on radiologic studies, advanced analytics like texture analysis have the potential to uncover tumor features that cannot be identified by visual assessment and can provide detailed characterization of the specific tissue or lesion of interest and the associated microenvironment. A recent proof-of-concept study reported that radiomics predicted pneumonitis in patients who received immunotherapy with an accuracy of 100%. 50 Finally, radiogenomics, the linkage between imaging phenotypes and tumor genomics, may assist in the development of more robust stratification and endpoint imaging biomarkers for molecular-targeted clinical trials.
CONCLUSIONS
The role of immunotherapy in treating patients with cancer continues to expand. Therefore, it is essential that radiologists and other providers have a thorough understanding of the novel response criteria developed to evaluate these patients, such as irRC, irRECIST, and iRECIST. In addition, because a wide variety of immune-related adverse events may affect patients who receive immunotherapy, the prompt identification and reporting of such side effects is imperative.
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